Literature DB >> 27002815

Botulinum toxin therapy: reduction of injection site pain by pH normalisation.

Dirk Dressler1, Fereshte Adib Saberi2, Hans Bigalke2,3.   

Abstract

Botulinum toxin (BT) is injected intramuscularily and may produce injection site pain (ISP). We wanted to explore whether the pH value of the reconstituted BT drug contributes to ISP and, if so, what strategies can be applied to reduce it. In part 1 of the study, pH values of different reconstitution solutions and of major BT drugs reconstituted with different reconstitution solutions were assessed. In part 2, the effects of reconstitution with normal saline (NS) and Ringer acetate (RA) were compared intraindividually and in a double blind fashion in 34 patients with blepharospasm. pH values of reconstitution solutions were 5.52 ± 0.02 for NS, 6.98 for RA, 6.31 for Ringer lactate, 6.56 for electrolyte and 5.31 for bacteriostatic solution. pH values for NS-reconstitution were 6.09 ± 0.20 for Botox(®), 5.95 ± 0.24 for Dysport(®) and 5.81 ± 0.18 for Xeomin(®). pH values for RA-reconstitution were 6.95 ± 0.03 for Botox(®), 7.01 ± 0.02 for Dysport(®) and 6.87 ± 0.06 for Xeomin(®). By using RA instead of NS the pH could be increased by 0.86 for Botox(®), by 1.06 for Dysport(®) and by 1.06 for Xeomin(®). 47 % of the patients experienced less ISP when Botox(®)-RA was given rather than Botox(®)-NS, 76 % when Xeomin(®)-RA was given rather than Xeomin(®)-NS. None of the patients reported a difference in efficacy between NS- and RA-reconstitution. Despite previous reports, reconstituted BT type A drugs show acidic pH values. Normalising these pH values by use of RA instead of NS reduces ISP considerably without sacrificing clincial efficacy.

Entities:  

Keywords:  Botulinum toxin; Normal saline; Reconstitution solution; Ringer acetate; Therapeutic use; pH value

Mesh:

Substances:

Year:  2016        PMID: 27002815     DOI: 10.1007/s00702-016-1522-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  7 in total

1.  Evaluating effects of preservative-containing saline solution on pain perception during botulinum toxin type-a injections at different locations: a prospective, single-blinded, randomized controlled trial.

Authors:  Nedim Sarifakioglu; Evren Sarifakioglu
Journal:  Aesthetic Plast Surg       Date:  2005-04-14       Impact factor: 2.326

2.  Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study.

Authors:  Shawn B Allen; Neil A Goldenberg
Journal:  Dermatol Surg       Date:  2012-01-23       Impact factor: 3.398

3.  Anesthesia with EMLA cream for botulinum A toxin injection into eyelids.

Authors:  Meltem F Söylev; Nilüfer Koçak; Bahar Kuvaki; Seyhan B Ozkan; Erkin Kir
Journal:  Ophthalmologica       Date:  2002 Sep-Oct       Impact factor: 3.250

4.  Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial.

Authors:  Murad Alam; Jeffrey S Dover; Kenneth A Arndt
Journal:  Arch Dermatol       Date:  2002-04

5.  Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study.

Authors:  J Vadoud-Seyedi; T Simonart
Journal:  Br J Dermatol       Date:  2007-02-07       Impact factor: 9.302

6.  Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial.

Authors:  S van Laborde; Jeffrey S Dover; Megan Moore; Brigitte Stewart; Kenneth A Arndt; Murad Alam
Journal:  J Am Acad Dermatol       Date:  2003-06       Impact factor: 11.527

7.  Botulinum toxin type B for treatment of axillar hyperhidrosis.

Authors:  Dirk Dressler; Fereshte Adib Saberi; Reiner Benecke
Journal:  J Neurol       Date:  2002-12       Impact factor: 4.849

  7 in total
  6 in total

Review 1.  Botulinum toxin drugs: brief history and outlook.

Authors:  D Dressler
Journal:  J Neural Transm (Vienna)       Date:  2015-11-11       Impact factor: 3.575

Review 2.  Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology.

Authors:  Marco Pirazzini; Ornella Rossetto; Roberto Eleopra; Cesare Montecucco
Journal:  Pharmacol Rev       Date:  2017-04       Impact factor: 25.468

3.  Clinical Pharmacology of Botulinum Toxin Drugs.

Authors:  Dirk Dressler
Journal:  Handb Exp Pharmacol       Date:  2021

4.  Strategies to decrease injection site pain in botulinum toxin therapy.

Authors:  Lejla Paracka; Katja Kollewe; Florian Wegner; Dirk Dressler
Journal:  J Neural Transm (Vienna)       Date:  2017-07-24       Impact factor: 3.575

5.  Injection Site Pain, Onset and Duration of Action of Botulinum Toxin Reconstituted in Normal Saline With and Without Sodium Bicarbonate: A Prospective, Single Center, Randomized, Double-Blind Interventional Study.

Authors:  Yazeed Alghonaim; Leen O Hijazi; Sondus A Alraee; Yasser Alqubaisy
Journal:  Plast Surg (Oakv)       Date:  2021-05-12       Impact factor: 0.558

6.  Assessing adverse effects of intra-articular botulinum toxin A in healthy Beagle dogs: A placebo-controlled, blinded, randomized trial.

Authors:  Helka M Heikkilä; Tarja S Jokinen; Pernilla Syrjä; Jouni Junnila; Anna Hielm-Björkman; Outi Laitinen-Vapaavuori
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.